T
IMRX icon

Tidemark’s Immuneering IMRX Stock Holding History

Tidemark’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.9K Hold
10,000
– – 0.01% 308
2026
Q1 		$52.7K Sell
10,000
-10,000
-50% -$51.3K 0.01% 262
2025
Q4 		$132K Sell
20,000
-24,400
-55% -$157K 0.04% 153
2025
Q3 		$311K Hold
44,400
– – 0.09% 98
2025
Q2 		$150K Hold
44,400
– – 0.05% 147
2025
Q1 		$67.5K Hold
44,400
– – 0.02% 204
2024
Q4 		$97.7K Sell
44,400
-7,450
-14% -$15.4K 0.04% 176
2024
Q3 		$129K Buy
+51,850
New +$75.4K 0.05% 144

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Tidemark's IMRX Position: Q2 2026 in Review

Tidemark held its Immuneering (IMRX) position steady in Q2 2026 at 10,000 shares worth $49.9K. The position accounts for 0.01% of the portfolio, ranked #308.

Tidemark first reported a position in IMRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $311K in Q3 2025. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Tidemark held 10,000 shares of Immuneering worth $49.9K as of Q2 2026.
  • Tidemark left its Immuneering share count unchanged in Q2 2026.
  • Immuneering made up 0.01% of Tidemark's portfolio in Q2 2026, its #308 holding.
  • Tidemark first reported a position in Immuneering in Q3 2024 and has held it in 8 quarters since.
  • Tidemark's Immuneering position peaked at $311K in Q3 2025.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.